Работы, цитирующие эту работу

Работ: 2

Работа: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

1. COVID-19 Vaccines - Current State and Perspectives

   Ibrokhim Y. Abdurakhmonov

   КнигаSARS-CoV-2 and COVID-19 ResearchIntechOpen eBooks2022Цитирований: 1

   ABIABI:AkademIndex/openalex/2026.other.451741

2. Cellular vesicles-based “all-in-one” vaccine platform triggers mucosal immunity against respiratory viruses

   Yanrong Gao, Jie Zhu, Jimao Zhai +7

   СтатьяBacterial Infections and VaccinesNano Today2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.003063